Elevation of endoglin (CD105) concentrations in serum of patients with liver cirrhosis and carcinoma

European Journal of Gastroenterology and Hepatology

Volumn 19, Issue 9, 2007, Pages 755-761

  Yagmur, Eray ^a   Rizk, Mohamed ^a   Stanzel, Sven ^a   Hellerbrand, Claus ^b   Lammert, Frank ^c   Trautwein, Christian ^a   Wasmuth, Hermann E ^a   Gressner, Axel M ^a  

^a UNIVERSITY HOSPITAL RWTH AACHEN   (Germany)

^b UNIVERSITY OF REGENSBURG   (Germany)

^c UNIVERSITY OF BONN   (Germany)

Author keywords

fetoprotein; CD105; Chronic liver disease; Endoglin; Hepatocellular carcinoma; Liver cirrhosis

Indexed keywords

ALPHA FETOPROTEIN; ENDOGLIN;

ADULT; AGED; ARTICLE; CANCER PATIENT; CHRONIC LIVER DISEASE; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; HIGH RISK PATIENT; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ANTIGENS, CD; CARCINOMA, HEPATOCELLULAR; FEMALE; HUMANS; LIVER CIRRHOSIS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; PRECANCEROUS CONDITIONS; RECEPTORS, CELL SURFACE; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL;

EID: 34547927931     PISSN: 0954691X     EISSN: None     Source Type: Journal    
DOI: 10.1097/MEG.0b013e3282202bea     Document Type: Article

References (39)

1. Wands JR. Prevention of hepatocellular carcinoma. N Engl J Med 2004; 351:1567-1570.
2. Tsukuma K, Hiyama T, Tanaka S, Nakao M, Yabuuchi T, Kitamura T, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 1993; 328:1797-1801.
3. Kubo S, Nishiguchi S, Hiroshashi K, Tanaka H, Tsukamoto T, Hamba H, et al. Clinical significance of prior hepatitis B virus infection in patients with hepatitis C virus-related hepatocellular carcinoma. Cancer 1999; 86:793-798.
4. American Cancer Society. Cancer facts and figures 1999. Atlanta, Georgia: American Cancer Society; 1999.
5. Johnson PJ, Williams R. Cirrhosis and the etiology of hepatocellular carcinoma. J Hepatol 1987; 4:140-147.
6. Pateron D, Ganne N, Trinchet JC, Aurousseau MH, Mal F, Meicler C, et al. Prospective study of screening for hepatocellular carcinoma in Caucasian patients with cirrhosis. J Hepatol 1994; 20:65-71.
7. Zhou L, Liu J, Luo F. Serum tumor markers for detection of hepatocellular carcinoma. World J Gastroenterol 2006; 28:1175-1181.
8. Tong MJ, Blatt LM, Kao VW. Surveillance for hepatocellular carcinoma in patients with chronic viral hepatitis in the United States of America. J Gastroenterol Hepatol 2001; 16:553-559.
9. Sherman M. Alphafetoprotein: an obituary [Editorial]. J Hepatol 2001; 16:715-717.
10. Yuen MF, Lai CL. Serological markers of liver cancer. Best Pract Res Clin Gastroenterol 2005; 19:91-99.
11. Sherman M, Peltekian KM, Lee C. Screening for hepatocellular carcinoma in chronic carriers of hepatitis B virus: incidence and prevalence of hepatocellular carcinoma in a North American urban population. Hepatology 1995; 22:432-438.
12. Gebo KA, Chander G, Jenckes MW, Ghanem KG, Herlong HF, Torbenson MS. Screening tests for hepatocellular carcinoma in patients with chronic hepatitis C: a systematic review. Hepatology 2002; 36:S84-S92.
13. Westphal JR, Willems HW, Schalwijk CJ, Ruiter DJ, de Waal RM. A new 180-kDa dermal endothelial cell activation antigen: in vitro and in situ characteristics. J Invest Dermatol 1993; 100:27-34.
14. Burrows FJ, Derbyshire EJ, Tazzari PL, Amlot P, Gazdar AF, King SW. Up-regulation of endoglin on vascular endothelial cells in human solid tumors: implications for diagnosis and therapy. Clin Cancer Res 1995; 1:1623-1634.
15. Meurer SK, Tihaa L, Lahme B, Gressner AM, Weiskirchen R. Identification of endoglin in rat hepatic stellate cells. J Biol Chem 2005; 280:3078-3087.
16. Miller DW, Graulich W, Karges B, Stahl S, Ernst M, Ramaswamy A. Elevated expression of endoglin, a component of the TGF-β-receptor complex, correlates with proliferation of tumor endothelial cells. Int J Cancer 1999; 81:568-572.
17. Barbara NP, Wrana JL, Letarte M. Endoglin is an accessory protein that interacts with the signaling receptor complex of multiple members of the transforming growth factor-beta superfamily. J Biol Chem 1999; 274:584-594.
18. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD 105 antagonizes the inhibitory signaling of transforming growth factor-beta1 on human vascular endothelial cells. FASEB J 2000; 14:55-64.
19. Li C, Guo B, Ding S, Rius C, Langa C, Kumar P. TNF alpha down-regulates CD 105 expression in vascular endothelial cells: a comparative study with TGFbeta1. Anticancer Res 2003; 23:1189-1196.
20. Nagy JA, Brown LF, Senger DR, Lanir N, Van de Water L, Dvorak AM, et al. Pathogenesis of tumor stroma generation: a critical role for leaky blood vessels and fibrin deposition. Biochim Biophys Acta 1989; 948:305-326.
21. Weidner N. Tumor vascularity and proliferation: clear evidence of a close relationship. J Pathol 1999; 189:297-299.
22. Batts KP, Ludwig J. Chronic hepatitis: an update on terminology and reporting. Am J Surg Pathol 1995; 19:1409-1417.
23. Schultz KF, Grimes DA. Bias and causal associations in observational research. Lancet 2002; 359:248-252.
24. Schultz KF, Grimes DA. Case-control studies: research in reverse. Lancet 2002; 359:431-434.
25. Okuda K, Ohtsuki T, Obata H, Tomimatsu M, Okazaki N, Hasegawa H, et al. Natural study of hepatocellular carcinoma and prognosis in relation to treatment, study of 850 patients. Cancer 1985; 56:918-928.
26. Graulich W, Nettelbeck DM, Fischer D, Kissel T, Müller R. Cell type specificity of the human endoglin promoter. Gene 1999; 227:55-62.
27. Fonsatti E, Sigalotti L, Arslan P, Altomonte M, Maio M. Emerging role of endoglin (CD 105) as a marker of angiogenesis with clinical potential in human malignancies. Curr Cancer Drug Targets 2003; 3:427-432.
28. Salvesen HB, Gulluoglu MG, Stefansson I, Akslen LA. Significance of CD 105 expression for tumor angiogenesis and prognosis in endometrial carcinomas. APMIS 2003; 111:1011-1018.
29. Saad RS, Liu YL, Nathan G, Celebrezze J, Medich D, Silverman JF. Endoglin [CD105] and vascular endothelial growth factor as prognostic markers in colorectal cancer. Mod Pathol 2004; 17:197-203.
30. Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME. Endoglin expression as a measure of microvessel density in cervical cancer. Obstet Gynecol 2000; 96:224-228.
31. Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M, et al. Correlation between apoptotic index and angiogenesis in non-small cell lung cancer: comparison between CD105 and CD34 as a marker of angiogenesis. Lung Cancer 2003; 39:289-296.
32. Dales JP, Garcia S, Carpentier S, Andrac L, Ramuz O, Lavaut MN, et al. Long-term prognostic significance of neoangiogenesis in breast carcinomas: comparison of Tie-2/Tek, CD105, and CD31 immunocytochemical expression. Hum Pathol 2004; 35:176-183.
33. Yu JX, Zhang XT, Liao YQ, Zhang QY, Chen H, Lin M, et al. Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 2003; 9:2866-2869.
34. Wikstrom P, Lissbrandt IF, Stattin P, Egevad L, Bergh A. Endoglin [CD105] is expressed on immature blood vessels and is a marker for survival in prostate cancer. Prostate 2002; 51:268-275.
35. Torsney E, Charlton R, Parums D, Collis M, Arthur HM. Inducible expression of human endoglin during inflammation and wound healing in vivo. Inflamm Res 2002; 51:464-470.
36. Warrington K, Hillarby MC, Li C, Letarte M, Kumar S. Functional role of CD105 in TGF-beta1 signalling in murine and human endothelial cells. Anticancer Res 2005; 25:1851-1864.
37. Clemente M, Nunez O, Lorente R, Rincon D, Matilla A, Salcedo M, et al. Increased intrahepatic and circulating levels of endoglin, a TGF-β1 co-receptor, in patients with chronic hepatitis C virus infection: relationship to histological and serum markers of hepatic fibrosis. J Viral Hepatol 2006; 13:625-632.
38. Yang L, Lu W, Huang G, Wang W. Correlation between CD105 expression and postoperative recurrence and metastasis of hepatocellular carcinoma. BMC Cancer 2006; 6:110.
39. Ho JW, Poon RT, Sun CK, Xue WC, Fan ST. Clinicopathological and prognostic implications of endoglin (CD105) expression in hepatocellular carcinoma and its adjacent non-tumorous liver. World J Gastroenterol 2005; 11:176-181.